For patients with type 2 diabetes and their physicians, fear of hypoglycaemia limits attainment of glycaemic targets,1, 2 increasing the risk of developing diabetes‐related complications.3 The last decade has witnessed a dramatic shift favouring the use of three newer classes of antihyperglycaemic agents (AHA) including the dipeptidyl peptidase IV inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP1RA) and sodium glucose co‐transporter 2 inhibitors (SGLT2i).4 For patients with type 2 diabetes, these AHA lower blood glucose with the promise of lower hypoglycaemia risk. The gene discussed is SLC5A2; the disease is Hypoglycemia.